RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsized, full-service contract research organization (CRO), announced today that Sherilyn Adcock, RPH, PHD, has been promoted to chief scientific officer, Early Phase Development.
In her new role, Dr. Adcock will provide key insight to our clinical development teams and to sponsors as they navigate the complexities of early phase drug development.
With a background in pharmacy and clinical operations, Dr. Adcock has dedicated her career to early phase development. Based in Austin, Texas, she has played a leading role in Worldwide’s growth since joining as director of clinical research in 2001. She has been an integral part of the company’s Early Phase business transformation from a small clinical site operation focused on generic compounds to the highly innovative business it is today. Dr. Adcock has been instrumental in expanding the Early Phase business to an integrated 200+- bed, highly flexible, fit for service, clinical pharmacology unit, pharmacy compounding services, specialty pharmacy services, and full bioanalysis laboratory renowned for its medical and scientific foundation and its services, staff, and accessibility.
“For the last 20 years, Sherilyn has forged a reputation for always keeping our customers’ needs front and center,” said Mike Mencer, executive vice president, Early Phase Drug Development, Worldwide Clinical Trials. “I am confident that her strong scientific acumen and deep drug discovery experience will bring an invaluable perspective in driving the next phase of our trajectory.”
Before joining Worldwide, Dr. Adcock served in executive clinical research roles for SCIREX Corporation and Biomedical Research Group (now Premier Research), Phoenix International Life Sciences (now Celerion), HealthQuest Therapy and Research Institute and Pharmaco International (now PPD).
Prior to entering clinical research, she spent several years working in hospital and clinical settings as a pharmacist and in development and oversight of specialty pharmacy services.
“I am privileged to work alongside the best of the best at Worldwide as we continue to give our all to the high-stakes, exciting field of early phase drug development,” Dr. Adcock said. “And, I’m proud of the value our medical and scientific focus brings to sponsors who are looking for a clinical partner willing to help guide them through the process. This combination will propel the next phase of Worldwide’s exceptional growth, and I am thrilled to be a part of it.”
Dr. Adcock earned her B.S. in pharmacy, a M.S. in health science, and a Ph.D. in community health and biostatistics, all from the University of Texas. She is licensed by the Texas State Board of Pharmacy and holds certifications in sterile product preparation, immunization, and pharmacogenomics.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs 2,000+ professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia-Pacific. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval, and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology, and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.